The GLG1 Knockout Raji Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population for studying GLG1 in Raji B lymphocytes. Generated via CRISPR/Cas9-mediated gene disruption, this loss-of-function model enables investigation of GLG1??s role in fibroblast growth factor (FGF) signaling and intra-Golgi trafficking. The polyclonal format preserves population diversity while abolishing GLG1 expression, offering a robust system for functional assays.
Raji cells, derived from a Burkitt??s lymphoma patient, are lymphoblastoid B lymphocytes that retain antigen presentation and antibody production capabilities. As a classic model for B-cell lymphoma research, they facilitate the exploration of oncogenic signaling and therapeutic vulnerabilities, making them ideal for probing genes like GLG1 that intersect with growth factor pathways.
GLG1 (MG160/CFR) is a Golgi-resident type I transmembrane protein that binds fibroblast growth factors FGF1 and FGF2, modulating their transport and presentation to FGFR1. It interacts with Golgi matrix components GOLGA2 and GORASP1 and the COPI coatomer, positioning it at the nexus of vesicular trafficking and glycoprotein biosynthesis. Upstream regulators include FGF ligands and ER stress sensors ATF6 and IRE1, while downstream targets encompass the RAS-RAF-MEK-ERK kinase cascade and the AKT-mTOR pathway. Through these interactions, GLG1 couples Golgi organization to FGF signal output and cellular metabolism.
In the Raji B-cell background, GLG1 knockout is predicted to disrupt FGF-dependent proliferative and survival signaling by attenuating ERK and AKT phosphorylation. This may lead to altered Golgi morphology and aberrant glycoprotein processing, potentially affecting B-cell transformation and immune function. The model provides a unique tool to dissect the contribution of Golgi-mediated growth factor regulation to B-cell lymphoma pathogenesis and to test sensitivities of malignant B cells to FGF pathway inhibition.
Applications include investigating FGF signaling in B-cell lymphoma, examining Golgi trafficking in immune cells, and screening for FGF-dependent growth mechanisms. Recommended assays are Western blotting for phospho-ERK and phospho-AKT, RT-qPCR for FGF target genes, immunofluorescence microscopy for Golgi structure, flow cytometry for cell cycle and apoptosis, and FGF stimulation assays. To receive further technical details or to purchase this product, please contact Ascent Research.
